Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Voyager Therapeutics (VYGR) EBITDA: 2014-2024

Historic EBITDA for Voyager Therapeutics (VYGR) over the last 11 years, with Dec 2024 value amounting to -$65.4 million.

  • Voyager Therapeutics' EBITDA fell 223.37% to -$27.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$126.7 million, marking a year-over-year decrease of 585.69%. This contributed to the annual value of -$65.4 million for FY2024, which is 149.33% down from last year.
  • According to the latest figures from FY2024, Voyager Therapeutics' EBITDA is -$65.4 million, which was down 149.33% from $132.5 million recorded in FY2023.
  • Voyager Therapeutics' EBITDA's 5-year high stood at $132.5 million during FY2023, with a 5-year trough of -$71.2 million in FY2021.
  • For the 3-year period, Voyager Therapeutics' EBITDA averaged around $6.9 million, with its median value being -$46.5 million (2022).
  • As far as peak fluctuations go, Voyager Therapeutics' EBITDA crashed by 293.95% in 2021, and later surged by 385.02% in 2023.
  • Over the past 5 years, Voyager Therapeutics' EBITDA (Yearly) stood at $36.7 million in 2020, then plummeted by 293.95% to -$71.2 million in 2021, then skyrocketed by 34.71% to -$46.5 million in 2022, then soared by 385.02% to $132.5 million in 2023, then tumbled by 149.33% to -$65.4 million in 2024.